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Nuclear factor kB (NF-kB)/Rel transcription factors
are key regulators of a variety of genes involved in im-
mune and inflammatory responses, growth, differentia-
tion, apoptosis, and development. In unstimulated cells,
NF-kB/Rel proteins are sequestered in the cytoplasm by
IkB inhibitor proteins. Many extracellular stimuli, such
as tumor necrosis factor a (TNFa), cause rapid phospho-
rylation of IkB at N-terminal serine residues leading to
ubiquitination and degradation of the inhibitor. Subse-
quently, NF-kB proteins translocate to the nucleus and
activate gene expression through kB response elements.
TNFa, as well as certain other stimuli, also induces the
phosphorylation of the NF-kB proteins. Previously, we
have shown that TNFa induces RelA/p65 phosphoryla-
tion at serine 529 and that this inducible phosphoryla-
tion increases NF-kB transcriptional activity on an ex-
ogenously supplied reporter (1). In this report, we
demonstrate that casein kinase II (CKII) interacts with
p65 in vivo and can phosphorylate p65 at serine 529 in
vitro. A CKII inhibitor (PD144795) inhibited TNFa-in-
duced p65 phosphorylation in vivo. Furthermore, our
results indicate that the association between IkBa and
p65 inhibits p65 phosphorylation by CKII and that deg-
radation of IkBa allows CKII to phosphorylate p65 to
increase NF-kB transactivation potential. These data
may explain the ability of CKII to modulate cell growth
and demonstrate a mechanism whereby CKII can func-
tion in an inducible manner.
The NF-kB1/Rel transcription factors play critical roles in
regulating the expression of a variety of genes involved in
immune and inflammatory responses, cell proliferation, and
apoptosis (2, 3). NF-kB was first identified as a constitutively
active transcription factor that binds to the immunoglobulin k
light chain enhancer in mature B cells (4). There are five
members of the mammalian Rel family of proteins that have
been cloned and characterized: RelA/p65, c-Rel, NF-kB1 (p50/
p105), NF-kB2 (p52/p100), and RelB (2, 3, 5). Each of these
proteins is characterized by a Rel homology domain (RHD),
which is involved in dimerization, DNA binding, interactions
with IkB, and nuclear localization. Several, but not all, of the
NF-kB proteins contain transcriptional activation domains,
which promote interactions with basal transcription compo-
nents or with transcriptional co-activators. For example, RelA/
p65 contains at least two transactivation domains in the C-
terminal region and an element in the RHD involved with
recruitment of co-activators (2, 3, 6).
In most unstimulated cells, NF-kB is sequestered in the
cytoplasm by IkB proteins that mask the nuclear localization
sequence of NF-kB (7–10). In response to various stimuli, the
IkB kinase (IKK) signaling cascade is activated, leading to the
phosphorylation of the N-terminal serine residues Ser32 and
Ser36 of IkBa (11–15). This phosphorylation promotes ubiquiti-
nation of the IkB proteins, which are subsequently targeted for
rapid degradation via the 26 S proteasome (2, 16). The degra-
dation of IkB then promotes nuclear translocation of NF-kB. In
the nucleus, NF-kB is a positive regulator of genes involved in
immune and inflammatory processes and cell proliferation.
Regarding the latter point, NF-kB is now known to regulate
transcription of cyclin D1 and c-Myc, to be activated by a
variety of oncoproteins, and to be required for oncogenesis or
tumorigenesis in different settings (17).
Interestingly, nuclear translocation and DNA binding are
apparently not sufficient to activate an NF-kB-dependent re-
porter. For example, it has been shown that inhibition of tyro-
sine kinase signaling inhibits the ability of interleukin-1 to
activate an NF-kB-dependent reporter but does not block nu-
clear translocation and DNA binding of NF-kB (18). Addition-
ally, it has been shown that inhibition of the p38 mitogen-
activated protein kinase pathway by the use of a small
molecule inhibitor blocks reporter activity but does not affect
nuclear translocation of NF-kB (19). Consistent with these
observations, it has been found that signals that activate
NF-kB can also cause the phosphorylation of NF-kB molecules
(6, 20–26). In vitro studies suggest that phosphorylation of p50
or p65 enhances NF-kB DNA binding ability (21, 23, 27). Work
by Zhong et al. (6) demonstrated that LPS induces PKA-de-
pendent phosphorylation of p65, increasing NF-kB transcrip-
tional potential in B and T cells. This phosphorylation leads to
the recruitment of the transcriptional coactivators CBP and
p300 (28). In this case, the catalytic subunit of PKA is found
associated with NF-kB, and PKA can phosphorylate p65 fol-
lowing IkB degradation. Another group has provided evidence
that IKK can phosphorylate RelA/p65 on serine 536 (29). Re-
cently, we have reported that TNFa treatment of fibroblasts
and HeLa cells leads to phosphorylation of p65 on serine 529,
which leads to increased transcriptional potential (1). Interest-
ingly, the sequence surrounding serine 529 fits the consensus
site for casein kinase II (CKII) phosphorylation.
CKII is a serine/threonine kinase, which is evolutionarily
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conserved from yeast to human (30). In most organisms, CKII
is a tetramer composed of two a (and/or a9) and two b subunits
(31, 32). Disruption of both genes encoding a and a9 subunits of
CKII in yeast results in a complete loss of cell viability (33),
indicating that CKII is essential. The consensus sequence for
CKII phosphorylation is serine (or threonine)-X-X-acidic,
where the acidic amino acid could be glutamic acid, aspartic
acid, phosphoserine, or phosphotyrosine (30). To date, more
than 100 proteins have been found to be substrates of CKII,
including several transcription factors. Phosphorylation of
transcription factors by CKII can affect their nuclear transport,
DNA binding, or transactivation abilities (30). For example,
phosphorylation of c-Jun by CKII negatively affects AP-1 DNA
binding ability (34), while PU.1 phosphorylation by CKII en-
ables its interaction with another transcription factor, NF-
EM5, to activate transcription (35). Recently, it has been shown
that overexpression of CKII enhances cell proliferation (36) and
tumor formation in a p53 null setting (37), providing compel-
ling evidence for a role for CKII in oncogenesis and cell growth.
CKII has been proposed to regulate NF-kB activity through
modulation of IkB. Thus, several laboratories have reported
that CKII constitutively phosphorylates the C-terminal PEST
region of IkBa (38–41). It was proposed that this phosphoryl-
ation is required for the basal turnover of the IkBa protein (39,
41). However, others found that the C-terminal region of IkBa
is dispensable for its degradation (42). CKII also causes induc-
ible phosphorylation of IkBa, since it was found that CKII
phosphorylates serine 32 of IkBa in response to TNFa or oka-
daic acid treatment of HeLa cells. Relevant to phosphorylation
of RelA/p65, Bird et al. (44) have reported that a kinase with
properties consistent with CKII activity associates with RelA/
p65 in fibroblasts and hepatoma cells and that purified CKII
can phosphorylate p65 in vitro.
In this study, we report that CKII phosphorylates p65 at
serine 529 following TNFa stimulation, although overall CKII
activity is only weakly increased in HeLa cells. We provide
evidence that, in unstimulated cells, the association of IkBa
with NF-kB inhibits CKII phosphorylation of p65. Signal-in-
duced degradation of IkBa releases this inhibition and enables
CKII to phosphorylate p65 on serine 529. These results provide
a rationale to explain the involvement of CKII with oncogenesis
and cell proliferation and offer a mechanism to explain induc-
ible CKII activity.
EXPERIMENTAL PROCEDURES
Cell Culture—HeLa cells and the stable cells that either express
F-p65 or F-529A (1) were grown in Dulbecco’s modified Eagle’s medium.
All media were supplemented with 10% fetal bovine serum, penicillin,
and streptomycin.
Immunoprecipitation—Cell lysates were made in cold radioimmuno-
precipitation assay buffer (1). Whole cell lysates were subjected to
immunoprecipitation with Flag M2-conjugated beads or CKII antibody
(Upstate Technologies) in protein A beads. The precipitated proteins
were separated in SDS-PAGE and transferred to nitrocellulose
(Schleicher & Schuell) for Western blot analysis. For the kinase assays,
the precipitated proteins were boiled in the presence of 1% SDS and 10
mM Tris-HCl (pH 7.6) for 5 min and subjected to another round of
immunoprecipitation before use in the kinase assay.
Electrophoretic Mobility Shift Assay and Western Blot Assay—Nu-
clear and cytoplasmic extracts were prepared as described previously
(45). Electrophoretic mobility shift assay was performed as previously
detailed (46). The DNA probe (1) contains the NF-kB binding site from
the major histocompatibility complex class I H-2kb gene. Western blot
analysis was performed by methods described elsewhere (1).
Transient Transfection and Luciferase Assay—HeLa cells were
transfected using SuperFect (Promega). For each transfection, 5 mg of
3XkBluc plasmid was incubated with 30 ml of SuperFect. Six hours
before harvest, TNFa (10 ng/ml) was added to the cells that have been
pretreated with PD144795 (gift of Dr. S. Hunt, Parke-Davis Pharma-
ceuticals, Ann Arbor, MI) or Me2SO for 1 h. Luciferase assays were
performed as described previously (47).
Plasmid Construct and Purification of Bacterially Expressed p65—
Plasmid pRSET-p65 was made by cloning the polymerase chain reac-
tion product into the BamHI site of pRSET B (Invitrogen). The template
for the polymerase chain reaction is pCMV-p65. The primers are 59-
CCG GGA TCC GAC GAA CTG TTC CCC CTC ATC-39 and 59-GGC
GGA TCC TTA GGA GCT GAT CTG ACT C-39. His-tagged p65 was
purified using His-Bind purification kits (Novagen).
In Vivo Labeling and Kinase Assay—For 32P metabolic labeling, cells
were grown in phosphate-free medium with 2% serum for 3 h.
PD144795 and [32P]H3PO4 were added 1 h before harvest. Cells were
harvested by the methods described elsewhere (1).
For CKII assay, immunoprecipitated p65 or bacterially expressed
His tagged p65 was incubated with CKII (Promega) at 37 °C for 10 min
in 25 mM Tris-HCl (pH 7.4), 0.2 M NaCl, 10 mM MgCl, 100 mM ATP, and
1 mCi of [g-32P]ATP. For PKA assay, the proteins were incubated with
PKA catalytic subunit (Promega) at 30 °C for 5 min in 40 mM Tris-HCl
(pH 7.4), 20 mM magnesium acetate, and 0.2 mM [g-32P]ATP. Phospho-
rylated p65 were resolved in SDS-PAGE. After exposure to x-ray film,
the gels were dried and analyzed by Western blot or by GELCODE blue
stain reagent (Pierce).
To assay for CKII activity, HeLa cells were either left untreated or
treated with TNFa for various times. Cell pellets were resuspended in
0.25 M Tris-HCl (pH 7.6). After repeated freeze-thaw, whole cell lysates
were collected by centrifuging. Whole cell lysates (50 mg) were used to
assay for casein kinase II activity by using a casein kinase-2 assay kit
(Upstate Biotechnology).
RESULTS
Casein Kinase II Interacts with p65 in Vivo—TNFa stimula-
tion of HeLa cells or fibroblasts induces phosphorylation of p65
on serine 529 (1). Close examination of the sequence down-
stream of serine 529 (SGDE) revealed that it is a consensus
CKII site (31, 32). Thus, the sequence matches the S-X-X-acidic
consensus motif for CKII phosphorylation. It was therefore
possible that CKII phosphorylates p65 in response to TNFa
induction. To test this possibility, we first determined if CKII
interacts with p65 in vivo. Flag-tagged p65 was immunopre-
cipitated from immortalized p65 knockout fibroblasts that have
been restored with flag-tagged p65 (F-p65 cells described in
Ref. 1), and the precipitated proteins were subjected to Western
blot analysis using an anti-CKII antibody. The results of these
experiments showed that the flag M2 antibody pulled down two
peptides recognized by the anti-CKII antibody (Fig. 1A, lane 1).
These two peptides represented the CKII catalytic subunits a
and a9, as the anti-CKII antibody was specifically made against
these two subunits. As a positive control, the anti-CKII anti-
body precipitated the same molecular weight peptides (Fig. 1A,
lane 2). The reciprocal co-immunoprecipitation, in which the
cell lysates were immunoprecipitated with an anti-CKII anti-
body and the precipitated proteins were analyzed by an anti-
p65 antibody, showed that the anti-CKII antibody co-immuno-
precipitated p65 (Fig. 1A, lane 4).
The data shown in Fig. 1A support and extend the previous
observation by Bird et al. (44), who showed that immunopre-
cipitated NF-kB complexes contained kinase activity that was
indistinguishable from CKII, although direct blotting for CKII
was not accomplished. Encouraged by this result, we then
wanted to determine whether TNFa stimulation of cells af-
fected the interaction between CKII and p65. To accomplish
this, F-p65 cells were either left untreated or were treated with
TNFa for various times. Whole cell lysates were subjected to
immunoprecipitation with flag M2 antibody, and the precipi-
tated proteins were analyzed by Western blot using the anti-
CKII antibody. As shown in Fig. 1B, the p65-associated CKII
level decreased upon TNFa induction (lanes 1–4). Interest-
ingly, the interaction between CKII and a mutant p65 (529A)
that cannot be phosphorylated following TNFa stimulation
remained constant (Fig. 1B, lanes 5–8), suggesting that serine
529 of p65 may be a target for CKII and that phosphorylation
of p65 may cause the release of CKII.
CKII Phosphorylates p65 at Serine 529—To determine
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whether CKII phosphorylates p65 at serine 529, both flag-
tagged wild-type p65 and p65 529A were immunoprecipitated
from the lysates of untreated cells and used for in vitro kinase
assays with purified CKII. As shown in Fig. 2A, CKII phospho-
rylated wild-type p65 (lanes 2 and 3, upper panel), but not 529A
(lanes 5 and 6, upper panel). Western blot analysis indicated
that the loss of phosphorylation of 529A by CKII is not due to
lower substrate protein levels (Fig. 2A, lower panel). Endoge-
nous p65 from HeLa cells can also be phosphorylated by CKII
(Fig. 2A, lane 8). Importantly, another serine/threonine kinase,
PKA, which has been reported to phosphorylate p65 (6), phos-
phorylated the mutant protein as efficiently as the wild-type
p65 (Fig. 2A, lanes 10 and 12). In addition, bacterially ex-
pressed His-tagged wild-type p65 but not 529A was phospho-
rylated by CKII, and this phosphorylation was inhibited by the
CKII-specific inhibitor PD144795 (see below) (Fig. 2B, left pan-
el), whereas PD144795 had no effect on PKA phosphorylation
of p65 (Fig. 2B, right panel). These results demonstrated that
CKII phosphorylates p65 in vitro and that phosphorylation
occurs at serine 529.
We then wanted to determine if CKII phosphorylates p65 in
vivo. To date, there are no reports in which CKII function can
be inhibited in vivo by genetic approaches. The difficulties
could result from the possibility that CKII a and a9 compensate
for each other, with disruption of either one not affecting over-
all CKII activity, while knockout of both leads to loss of viabil-
ity, as in yeast cells (33, 48). Therefore, we chose a pharmaco-
logical approach to determine if we could block TNFa-induced
p65 phosphorylation. PD144795 is a benzothiophene, which
was originally found to inhibit HIV expression (50). The selec-
tive target for inhibition was later found to be CKII, as this
compound interacts with the kinase at the nucleotide binding
site (51). Consistent with previous reports (50), we found that
PD144795 did not affect TNFa-induced NF-kB nuclear trans-
location and DNA binding in HeLa cells (Fig. 3A). However,
PD144795 inhibited kB-dependent transcription (Fig. 3B).
Moreover, pretreatment of HeLa cells with PD144795 de-
creased TNFa-induced p65 phosphorylation (Fig. 3C). These
results suggested that CKII phosphorylates p65 in response to
TNFa induction in HeLa cells.
Evidence for a Requirement of IkBa Degradation for RelA/
p65 Phosphorylation on Ser529—Our original study utilized
phosphopeptide mapping to identify serine 529 as the major
site of TNF-induced phosphorylation (1). Recently, another
group has reported that IKK can phosphorylate p65 both in
vivo and in vitro on serine 536 (29). In order to confirm that
serine 529 is phosphorylated in response to TNFa stimulation,
we generated an antibody to a peptide with phosphoserine at
position 529. Immunoblotting with this antibody confirms rec-
ognition of phosphoserine 529 following TNFa stimulation of
HeLa cells (Fig. 4). Thus, it is clear that serine 529 is a major
site of phosphorylation following TNFa treatment of HeLa cells
or fibroblasts (see “Discussion”).
We then utilized this antibody to determine if inducible
phosphorylation of RelA/p65 on serine 529 requires release
from IkBa. Potentially such a result could explain how CKII
could be associated with p65 but not phosphorylate this sub-
strate. In order to test this hypothesis, we treated cells with the
proteasome inhibitor MG132 and then stimulated the cells
with TNFa. Control cells were exposed to the diluent for
MG132 but still received TNFa. As shown in Fig. 4, TNFa
induced phosphorylation on Ser529, with phosphorylation peak-
ing at 10 min after stimulation. MG132 inhibited the induced
phosphorylation, suggesting that IkB degradation is required
for inducible phosphorylation. Additionally and consistent with
this hypothesis, expression of the super-repressor (non-degrad-
able) form of IkBa significantly blocked the TNFa-induced
phosphorylation of p65 (data not shown).
IkBa Inhibits p65 Phosphorylation by CKII—Regulation of
CKII activity has been difficult to explain. There have been
reports that CKII activity is constitutive and is not subjected to
regulation (31, 32, 52). However, other studies indicated that
stimulation of CKII activity can occur in response to growth
factors such as insulin-like growth factor 1 (53) and epidermal
growth factor (54). It was important for us to determine if
TNFa-induced p65 phosphorylation correlated with increased
CKII activity. HeLa cells were treated with TNFa for various
times, and cells were lysed by repeated freeze-thaw to avoid
detergent that may interfere with the kinase assay. Whole cell
lysates were then subjected to Western analysis with anti-CKII
antibody (Fig. 5A), and CKII activity was measured using a
synthetic CKII substrate (Fig. 5B). Unlike a recent report (43),
we were not able to detect a significant increase in CKII activ-
ity in response to TNFa induction. Instead, the CKII protein
level was unchanged and kinase activity was only slightly
induced following TNFa stimulation.
In order to explain the inducible activation of CKII activity
relevant to NF-kB phosphorylation and to explain the result
showing that inhibition of IkB degradation inhibited inducible
activity, we hypothesized that the association of CKII with the
NF-kB complex leads to inhibition of kinase activity if IkB is
present. To test our hypothesis, glutathione S-transferase-
IkBa was added to the in vitro CKII kinase reaction. As shown
in Fig. 5C, the addition of IkBa efficiently inhibited p65 phos-
phorylation by CKII. Therefore, these data indicate that when
CKII is present in the NF-kB/IkB complex, it cannot phospho-
rylate p65. Induction of IkBa degradation would, therefore,
lead to derepression of CKII activity, allowing it to phospho-
rylate p65.
DISCUSSION
The current understanding of the regulation of the transcrip-
tion factor NF-kB indicates that NF-kB is activated by two
mechanisms that appear to be interrelated. One mechanism
FIG. 1. CKII interacts with p65 in vivo. A, untreated cell lysates
from the cells expressing F-p65 were subjected to immunoprecipitation
(IP) with either anti-flag antibody (ab) (lanes 1 and 3) or CKII antibody
(lanes 2 and 4). The precipitated proteins were further analyzed by
Western blot using either CKII antibody (left) or p65 antibody (right). B,
the F-p65 cells or F-529A cells were either left untreated or treated with
TNFa for various times. The whole cell lysates were subjected to im-
munoprecipitation (IP) using anti-flag antibody (ab). The precipitated
proteins were separated on SDS-PAGE and analyzed by Western blot
with anti-CKII antibody.
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involves the induction of NF-kB to move into the nucleus fol-
lowing exposure of cells to a variety of stimuli. This mechanism
is controlled by the activation of IKK activity, which subse-
quently phosphorylates IkB proteins on N-terminal serine res-
idues leading to their ubiquitination and the subsequent deg-
radation of IkB (3). A less well understood regulation of NF-kB
involves induced phosphorylation of RelA/p65 in response to a
variety of stimuli. Interestingly, it is speculated that phospho-
rylation may be required for transcriptional function of NF-kB.
Thus, Zhong et al. (6, 28) showed convincingly that LPS induces
phosphorylation of RelA/p65 on Ser276 in B and T cells and that
this phosphorylation enhances the interaction with the tran-
scriptional co-activators CBP and p300. The phosphorylation of
Ser276 is controlled by the catalytic subunit of PKA associated
with the NF-kB complex. Similar to the model proposed here
for phosphorylation of p65 by CKII, it is proposed that degra-
dation of IkB allows the PKA catalytic subunit to phosphoryl-
ate RelA/p65 on Ser276. Sizemore et al. (26) showed that phos-
phorylation of p65 induced by interleukin-1 requires
phosphatidylinositol 3-kinase and Akt and that this response
activates the transcription function of NF-kB. Another group
has presented data indicating that IKK itself may be involved
directly in inducible phosphorylation of p65, showing that IKK
can phosphorylate serine 536 in vitro and when overexpressed
in cells (29). However, there are no data demonstrating that
this phosphorylation event contributed to transcriptional po-
tential. Previously, we have shown that phosphorylation of
serine 529 contributes to the ability of p65 to activate a kB-de-
pendent reporter. Others have provided evidence that phospho-
rylation of NF-kB may enhance DNA binding, although in our
previous studies we did not see an effect of mutation of serine
529 on DNA binding affinity (1).
We have shown in this report that the serine/threonine ki-
nase CKII interacts with p65 in vivo, and purified CKII phos-
phorylates p65 at serine 529 in vitro. A CKII inhibitor reduced
TNFa-induced p65 phosphorylation, suggesting that CKII
phosphorylates p65 in response to TNFa stimulation in vivo.
The results presented in this paper also suggest an interesting
mechanism by which the activity of CKII is regulated. Our data
indicate that CKII is associated with the NF-kB/IkB complex
but is unable to phosphorylate p65 unless IkBa is degraded. It
is presently unknown whether CKII directly interacts with p65
or with IkB or possibly both.
CKII is a ubiquitous and highly conserved serine/threonine
kinase which phosphorylates a number of nuclear proteins
implicated in cell proliferation, such as c-Fos, c-Jun, Myc, Max,
Myb, p53, adenovirus E1A protein, human papilloma virus E7
protein, and SV40 large T antigen (30). The effect of CKII
phosphorylation varies depending on the protein. For example,
CKII phosphorylates the transcriptional regulatory factor Max
to inhibit the DNA binding activity of Max/Max homodimers
(55), while phosphorylation of PU.1 by CKII promotes the in-
teraction with NF-EM5 (35). We have shown that p65 is also a
substrate for CKII and phosphorylation of p65 by CKII in-
creases NF-kB transcriptional potential. RelA/p65 has been
shown to be phosphorylated in response to interleukin-1 and
LPS induction (20), and the putative p65 kinase that associates
with both NF-kB and IkB has a molecular size that is very
similar to the CKII a subunit (27). More recently, Bird et al.
(44) demonstrated that a kinase with properties indistinguish-
able from CKII associates with p65 and phosphorylates it in
vitro. As described above, it has been published recently that
LPS-induced p65 phosphorylation by PKA at serine 276 en-
hances its interaction with the transcriptional coactivator CBP/
p300 (6, 28). Why different signals target different phosphoryl-
ation sites on p65 is presently unknown, but may be explained
by differences in cell types or differences in signal transduction
pathways.
FIG. 2. CKII phosphorylates p65 at serine 529. A, p65 proteins were immunoprecipitated from F-p65 cells, F-529A cells, or HeLa cells. In
vitro kinase assays were performed on the beads by adding [g-32P]ATP and purified CKII (C) (lanes 2, 3, 5, 6, and 8) or PKA (A) catalytic subunit
(lanes 10 and 12). Phosphorylated p65 was resolved on SDS-PAGE. After exposure to x-ray film, the gel was re-hydrated and analyzed by Western
blot with p65 antibody (left lower panel). B, bacterially expressed His-tagged wild type p65 (Wt) or 529A (A) was incubated with [g-32P]ATP and
CKII (left) or PKA catalytic subunit (right). Increased amounts of PD144795 were added to the kinase reaction (lanes 3–6). Phosphorylated p65
was separated on SDS-PAGE. After exposure to x-ray film, the gel was re-hydrated and analyzed by GELCODE blue stain reagent (Pierce).
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It has been shown before that CKII phosphorylates IkBa at
its C-terminal PEST region on several serine and threonine
residues and the function of this modification is unknown,
although some researchers suggested that the phosphorylation
of the PEST region by CKII is required for the basal turnover
of the free IkBa proteins (38–40, 42). CKII also phosphorylates
the PEST domain of IkBb (56, 57), which is required for IkBb to
associate with c-Rel or other NF-kB subunits to inhibit NF-kB
DNA binding. Recently, CKII was shown to be present in the
kinase activities that phosphorylated IkBa at serine 32 along
with p90rsk1 and IKKa/b (43) in the TNFa- or okadaic acid-
stimulated HeLa cell extracts. In the in vitro kinase assay,
CKII phosphorylates serine 32 of the IkBa-derived peptide
much more efficiently than serine 36 or any of the other IkBb
or IkBe-derived peptides. CKII may act alone or cooperate with
another kinase to induce the N-terminal serine phosphoryla-
tion and subsequent degradation of IkBa in response to some
stimuli. Therefore, CKII appears to regulate NF-kB at two
levels: 1) by phosphorylating IkBa to induce its degradation,
and 2) by phosphorylating p65 to increase NF-kB transcrip-
tional activity.
CKII has been shown to be necessary for cell cycle progres-
sion and for cell proliferation. CKII levels are elevated in rap-
idly proliferating non-neoplastic tissue and in solid tumors
such as colorectal carcinomas, malignant melanomas, and
bladder, kidney, gastric, and breast carcinomas (58). In trans-
genic mice, CKII cooperates with Tal-1 and c-Myc oncogenes to
induce lymphoma (59, 60). NF-kB also plays an important role
in cell proliferation. Elevated levels of NF-kB have been corre-
FIG. 3. A CKII-specific inhibitor, PD144795, inhibits kB-
dependent transcription and reduces TNFa-induced p65 phos-
phorylation. A, HeLa cells were pretreated with Me2SO (DMSO, lanes
5–9) or 20 mM PD144795 (lanes 10–14) before treatment with TNFa (10
ng/ml) for 10 min. The nuclear extracts were analyzed by electro-
phoretic mobility shift assay with a 32P-labeled kB site containing DNA
probe, and antibodies (ab) against different NF-kB subunits were
added. The reaction mixtures were electrophoresed on a 5% non-dena-
turing gel. B, HeLa cells were transiently transfected with a 3XkBluc
reporter that contains three copies of the kB binding site. Six hours
before harvest, TNFa (10 ng/ml) was added to the transfected cells that
had been pretreated with PD144795. Luciferase activities were meas-
ured using 100 mg of lysates. C, HeLa cells were labeled with
[32P]H3PO4, and either left untreated or treated with various amounts
of PD144795. Ten minutes before harvest, TNFa (40 ng/ml) was added.
The whole cell lysates were immunoprecipitated with anti-p65 antibody
and separated on SDS-PAGE. Phosphorylated p65 was visualized by
autoradiography.
FIG. 4. Proteasome inhibition abolishes inducible p65 phos-
phorylation at serine 529. HeLa cells were treated with TNFa for the
times indicated, in either the presence or absence of the proteasome
inhibitor MG132. Whole cell protein extracts were isolated and resolved
by SDS-PAGE. The gel was analyzed by Western blot with an antibody
specific to p65 phosphorylated at serine 529. The gel was then stripped
and reprobed with an antibody against IkBa to show that MG132
inhibits IkBa degradation. Anti-tubulin was used to verify equal pro-
tein loading.
FIG. 5. IkBa inhibits p65 phosphorylation by CKII. HeLa cells
were either left untreated or treated with TNFa for various times.
Whole cell lysates were made, and 50 mg of lysates were analyzed by
Western blot using anti-CKII antibody (A) and in vitro kinase assay
using a CKII substrate peptide (B). C, His-tagged p65 was used for
kinase assay with purified CKII. Different amounts of glutathione
S-transferase (GST)-IkBa were added to the reaction. The phosphoryl-
ated proteins were resolved on SDS-PAGE and visualized by autora-
diography (upper panel). The dried gel was re-hydrated and equal
loading of His-p65 was shown by staining the gel with GELCODE blue
stain reagent (Pierce) (lower panel).
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lated with cellular transformation (61, 62), and NF-kB has
been shown to be required for transformation induced by onco-
genic Ras and by the fusion oncoprotein BCR-ABL (49, 63). It
will be interesting to determine if CKII cooperates with NF-kB
to regulate cell transformation and tumorigenesis and if the
phosphorylation of the p65 subunit by CKII is necessary for the
cooperation.
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